health pharma news today obesity drugs glp-1 GLP‑1 real‑world data for obesity: A new standard for metabolic care A new oral GLP-1 option

According to the company, each capsule contains 500mcg of BPC-157, providing a standardized dose

Cells of origin in the embryonic nerve roots for NF1-associated plexiform neurofibroma

We did not find a significant non-linear relationship between dose (g/day) (coefficients = 1.72, p = 0.154) and changes in FBG, but we found a significant non-linear relationship (coefficients = 7.45, p = 0.020) between duration of intervention and changes in FBG, It seems that the effective duration for decreasing of FBG is 50 weeks (Figures 4A, 5A)

The choice often depends on individual health needs, severity of condition, and personal preferences for treatment modality